Astrazeneca (AZN) Consolidated Net Income (2016 - 2026)

Astrazeneca has reported Consolidated Net Income over the past 16 years, most recently at $3.9 billion for Q1 2026.

For Q1 2026, Consolidated Net Income rose 15.05% year-over-year to $3.9 billion; the TTM value through Mar 2026 reached $12.9 billion, up 38.96%, while the annual FY2025 figure was $10.2 billion, 45.33% up from the prior year.
Consolidated Net Income for Q1 2026 was $3.9 billion at Astrazeneca, up from $2.6 billion in the prior quarter.
Over five years, Consolidated Net Income peaked at $3.9 billion in Q1 2026 and troughed at $247.0 million in Q2 2022.
A 5-year average of $2.0 billion and a median of $2.1 billion in 2023 define the central range for Consolidated Net Income.
Biggest five-year swings in Consolidated Net Income: tumbled 67.67% in 2022 and later surged 745.34% in 2023.
Year by year, Consolidated Net Income stood at $778.0 million in 2022, then rose by 15.3% to $897.0 million in 2023, then surged by 85.73% to $1.7 billion in 2024, then skyrocketed by 57.8% to $2.6 billion in 2025, then surged by 48.88% to $3.9 billion in 2026.
Business Quant data shows Consolidated Net Income for AZN at $3.9 billion in Q1 2026, $2.6 billion in Q4 2025, and $3.2 billion in Q3 2025.

Peer Comparison